Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
African trypanosomiasis is a deadly neglected disease caused by the extracellular parasite Trypanosoma brucei. Current therapies are characterized by high drug toxicity and increasing drug resistance mainly associated with loss-of-function mutations in the transporters involved in drug import. The introduction of new antiparasitic drugs into therapeutic use is a slow and expensive process. In contrast, specific targeting of existing drugs could represent a more rapid and cost-effective approach for neglected disease treatment, impacting through reduced systemic toxicity and circumventing resistance acquired through impaired compound uptake. We have generated nanoparticles of chitosan loaded with the trypanocidal drug pentamidine and coated by a single domain nanobody that specifically targets the surface of African trypanosomes. Once loaded into this nanocarrier, pentamidine enters trypanosomes through endocytosis instead of via classical cell surface transporters. The curative dose of pentamidine-loaded nanobody-chitosan nanoparticles was 100-fold lower than pentamidine alone in a murine model of acute African trypanosomiasis. Crucially, this new formulation displayed undiminished in vitro and in vivo activity against a trypanosome cell line resistant to pentamidine as a result of mutations in the surface transporter aquaglyceroporin 2. We conclude that this new drug delivery system increases drug efficacy and has the ability to overcome resistance to some anti-protozoal drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis
Arias, J. L., Unciti-Broceta, J. D., Maceira, J., del Castillo, T., Hernández-Quero, J., Magez, S., Soriano, M., & García-Salcedo, J. A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.002 · Cited by 88 · cited 1×
“As previously reported [11], its chain length (26 nm) allows the nanobody linked to the NPs to reach its recognition epitope concealed within the densely packed VSG surface coat (about 10–15 nm thick) acting as an anchor rope for the nanoparticle.”
BackgroundSelf-citation
Cited by
Chitosan-Based Nanomaterials for Drug Delivery
Li, J., Cai, C., Li, J., Li, J., Li, J., Sun, T., Wang, L., Wu, H., & Yu, G. (2018) · Molecules · doi:10.3390/molecules23102661 · Cited by 481
Nanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 468
The animal trypanosomiases and their chemotherapy: a review
GIORDANI, F., MORRISON, L. J., ROWAN, T. G., DE KONING, H. P., & BARRETT, M. P. (2016) · Parasitology · doi:10.1017/s0031182016001268 · Cited by 447
Self-citationNANOBODIES®: A Review of Diagnostic and Therapeutic Applications
Jin, B.-K., Odongo, S., Radwanska, M., & Magez, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065994 · Cited by 371
Self-citationDemeu, L. M. K., Soares, R. J., Miranda, J. S., Pacheco-Lugo, L. A., Oliveira, K. G., Cortez Plaza, C. A., Billiald, P., Ferreira de Moura, J., Yoshida, N., Alvarenga, L. M., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0223773 · Cited by 7
Insights from aquaporin structures into drug-resistant sleeping sickness
Matusevicius, M., Corey, R. A., Gragera, M., Yamashita, K., Sprenger, T., Ungogo, M. A., Blaza, J. N., Castro-Hartmann, P., Chirgadze, D. Y., Chaitanya Vedithi, S., et al. (2025) · doi:10.1101/2025.05.15.654314 · Cited by 1
Self-citationInsights from aquaporin structures into drug-resistant sleeping sickness
Matusevicius, M., Corey, R. A., Gragera, M., Yamashita, K., Sprenger, T., Ungogo, M., Blaza, J. N., Castro-Hartmann, P., Chirgadze, D. Y., Chaitanya Vedithi, S., et al. (2026) · eLife · doi:10.7554/elife.107460.3 · Cited by 1
Self-citationInsights from aquaporin structures into drug-resistant sleeping sickness
Matusevicius, M., Corey, R. A., Gragera, M., Yamashita, K., Sprenger, T., Ungogo, M., Blaza, J. N., Castro-Hartmann, P., Chirgadze, D. Y., Chaitanya Vedithi, S., et al. (2026) · eLife · doi:10.7554/elife.107460 · Cited by 1
Self-citation
Metadata
- Authors
- Unciti-Broceta, J. D., Arias, J. L., Maceira, J., Soriano, M., Ortiz-González, M., Hernández-Quero, J., Muñóz-Torres, M., de Koning, H. P., Magez, S., & Garcia-Salcedo, J. A.
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-06-25
- Volume
- 11
- Issue
- 6
- Pages
- e1004942
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W1882489076
- Cited by
- 76
- References
- 1
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.